Online Enquiry
Subscribe
Log in / New User
Retrieve Password
此页面上的内容需要较新版本的 Adobe Flash Player。
切换导航
Home
Pharma China Web Edition
Pharma China Archives
Online Databases
Subscription/Download
Event Calendar
China Pharma Providers
About Us
Location:
Home
> Pharma China Web Edition
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Feature articles
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
Editor's Picks
Full Text
Title
Subscribe to Pharma China
Online Enquiry
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
Editor's Picks
ONLINE ENQUIRY
WiCON International Group
Bellevue, WA 98007, USA
info@pharmachinaonline.com
WiCON International Co. Ltd.
Osaka, Japan
info@pharmachinaonline.com
Product/R&D News
3/25/2025
Everest Announces FDA Clearance of IND Application for Tumor-Associate...
3/25/2025
BrightGene Initiates Phase II Head-to-Head Study of AI-Designed BGM050...
3/24/2025
FDA Rejects HLB Group's Liver Cancer Drug, Highlighting Regulatory and...
3/24/2025
SineuGene's SNUG01 Gene Therapy Receives FDA IND Approval for ALS Clin...
3/24/2025
GenScript's RA Drug Candidate Receives FDA Clearance for Clinical Tria...
3/21/2025
NMPA Approves Hutchmed's Tazverik for r/r Follicular Lymphoma in China
3/21/2025
Junshi's Toripalimab Receives 11th Approval in China
3/21/2025
Huadong Medicine's HDM1002 Advances to Phase III Clinical Trials
3/21/2025
AZ's Calquence (Acalabrutinib) Receives New Approval in China for Firs...
3/21/2025
Gilead's Trodelvy Receives Second Approval in China
3/21/2025
Hengrui's Ivarmacitinib Secures First Approval in China for Ankylosing...
3/21/2025
Henlius' HER2-Targeting Antibody HLX22 Granted FDA Orphan Drug Designa...
3/21/2025
Dizal's Golidocitinib in Combo with Anti-PD-1 Shows Promise in IO Resi...
3/21/2025
Innovent and Hutchmed's FRUSICA-2 Study Achieves Primary Endpoint
3/20/2025
Grand Pharma Advances Phase III Trial of ITM-11 in China
3/19/2025
Visirna's VSA001 Achieves Positive Phase III Results in Treating FCS
3/19/2025
CSPC Initiates Phase 3 Trial of SYS6010 for EGFR-Mutant NSCLC Patients
3/19/2025
Hengrui Initiates Phase 2/3 Trial Combining SHR-A2102 and Adebrelimab ...
3/17/2025
Innovent Launches GLORY-3: A Phase 3 Head-to-Head Study of Mazdutide v...
3/17/2025
Visirna Announce Positive Topline Results from Phase 3 Trial of Ploza...
3/17/2025
SinoCellTech Advances PD-1/VEGF Bispecific SCTB14 into Phase 2/3 for E...
3/17/2025
BeiGene and Amgen Launch Phase 1 Trial of Tarlatamab + YL201 in China
3/14/2025
Innovent's IBI311 Becomes First Chinese-Made IGF-1R Antibody Approved ...
3/14/2025
Zai Lab/Pfizer's BLA for Tivdak Accepted in China
3/14/2025
Pyrotech's PTT-936 Gains Approval for Clinical Trials in China for Adv...
3/14/2025
Roche's Itovebi (Inavolisib) Wins Approval in China for Advanced Breas...
3/13/2025
AskBio Receives FDA Regenerative Medicine Advanced Therapy designation...
3/12/2025
Novartis' Cosentyx Receives Fifth Indication Approval in China for Hid...
3/12/2025
Pfizer's PD-L1 Targeting ADC Receives Clinical Trial Approval in China
3/12/2025
CSPC Advances Phase II Trial of Nectin-4 ADC SYS6002 for Advanced HNSC...
Page:
2
/
11
Total number of articles:
316
:
[First]
[<<]
[1]
[2]
[3]
[4]
[5]
[>>]
[End]
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
FEATURE ARTICLES
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
Editor's Picks
GENERAL INFORMATION
TERMS & CONDITIONS OF USE
Download Info
Contact Us
Site map
|
Contact Us
|
Links
© Wicon International Group
×
Join the mailing list
We will e-mail you the most critical news and developments about China's healthcare sector, in real time and absolutely free.
name:
e-mail:
company:
submit